ReviewCurrent gastroenterology reports2026
Body Surface Gastric Mapping Improves Diagnosis of Gastric Motility Disorders.
Review in Current gastroenterology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewChronic gastroduodenal symptoms affect > 7% of adults, yet current diagnostic frameworks are challenged by limited mechanistic specificity, weak symptom correlation, and variable reproducibility. This review evaluates how body surface gastric mapping (BSGM), a non-invasive technology combining high-resolution gastric myoelectrical recording with validated symptom profiling, may improve the diagnosis and management of gastric motility disorders. RECENT
findingsBSGM employs a high-resolution 64-electrode array to derive validated biomarkers of gastric motor function, including rhythm stability, frequency, and amplitude, alongside standardised digital symptom and psychometric profiling. A recent international consensus ('Auckland Classification v1.0'), derived from over 50 published studies and 4,500 + clinical tests, defined six BSGM phenotypes encompassing putative mechanisms of neuromuscular dysfunction, visceral hypersensitivity, centrally-mediated symptoms, and small bowel contributions. BSGM significantly increases diagnostic yield for motility disorders and appears synergistic with gastric emptying testing in joint studies. Observational data currently indicate that BSGM-guided management changes clinical decisions in ~ 80% of patients and is associated with reduced healthcare utilisation. Key benefits include capability to aid discrimination of motor vs sensory disorders, with specific phenotypes provisionally linked to differential treatment responses. Paediatric studies show concordant phenotype patterns, with BSGM dysrhythmia identified as a more severe phenotype. BSGM provides mechanism-based phenotyping that extends gastroduodenal evaluation beyond symptom classifications and gastric emptying status. Prospective validation of phenotype-guided treatment algorithms is now underway, and integrated multimodal diagnostic frameworks incorporating BSGM alongside complementary investigations are likely to reshape the clinical approach to these challenging disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.